WTO,the Trips and Indian Pharmaceutical Industry

This paper analyzes the efficiency of firms in Indian Pharmaceutical Industry before and after the Trade Related Intellectual Property Rights (TRIPs) agreement. The analysis reveals that the efficiency of firms has increased after the Indian legislature has passed the bill for accepting patent applications in early 1999. We find that R&D intensity and market share influence efficiency of firms. The impact of import intensity enhances inefficiency. Our result indicates absence of ownership effects after the Indian legislature had passed the bill for accepting patent applications.

     

医药制造业发明专利与产业发展的空间耦合协调研究

专利与产业协调发展对实现产业创新发展至关重要。采用改进的象限图法以及专利重心与产业重心空间耦合态势模型,定量分析我国医药制造业发明专利与产业发展之间的耦合协调关系以及两者的时空动态演变趋势。结果表明,目前我国医药制造业发明专利与产业发展间存在明显偏离,耦合协调性主要表现为西高东低、北高南低的分布格局;近5年来,耦合协调性有所提高,发明专利重心与产业发展重心间的距离逐渐缩小,变动一致性提高。结论可为专利密集型产业、高技术产业专利与产业协调发展提供理论和实证支持。     

Financialization in the American Pharmaceutical Industry: A Veblenian Approach

Thorstein Veblen’s theory of the business enterprise holds that business interests come to dominate industrial interests, with pecuniary returns being the dominant mindset under which economic activity is conducted. Under moneymanager capitalism, this is reflected in the increasing importance of profits from financial channels and the accumulation of intangible rent-generating assets to serve as the basis for capitalization — a process known as financialization. I examine this process of intangible asset accumulation within the context of the American pharmaceutical industry using Veblen’s theory of the business enterprise as a lens. I show that intangible assets have come to dominate productive capital on pharmaceutical enterprise balance sheets, suggesting that pharmaceutical profits are accumulated through rent-seeking channels rather than productive ones, in line with Veblen’s theory, and provide evidence of the financialization of this industry.     

Product Patent Reform and its Impact on Korea's Pharmaceutical Industry

Our analysis focuses on the effect of U.S. government pressure on Korea to adopt product patents for chemical and pharmaceutical products. American pressure began in November 1985 and ended with the Korean Legislature's passage of a new patent law in December 1986. We conduct an event study of the effect of the new patent law on the value of Korean pharmaceutical firms listed on the Korea Stock Exchange. Regression analysis shows that the new law induced excess returns of-74 percent over the 14-month analysis period. The results suggest that adoption of stronger patent laws reduced Korea's wealth. [G14, O34]     

研发投入与上市公司业绩——基于机械设备业和生物医药业的比较研究

以2003—2007年在上交所上市的机械设备仪器制造业和医药生物制品业企业为样本,对研发投入与公司业绩之间的关系进行实证研究和比较分析。研究发现,研发人员投入与机械设备企业业绩的相关性程度和持续性远远大于生物医药企业;生物医药企业的业绩对研发资金投入的敏感性较强;研发资金投入对企业业绩作用的滞后性在生物医药行业比较明显。此外,相对于收入增长能力,研发投入与企业盈利能力和资产运作效率有更强的正相关关系。研究结论对企业优化其研发投入结构、对政府制定更有针对性的技术创新鼓励政策具有一定借鉴意义。     

河北省医药产业物流指数分析

医药产业物流指数是采用医药业的物流成本与产业总产值的比值来定义的,并以此衡量河北医药业的物流发展速度和物流质量,体现河北医药业的经济效率。从竞争性因素、产品因素、环境因素、管理因素等多个角度对河北省医药产业物流成本的构成进行详细分析,运用结构模型对物流成本的构成因素进行层次化、条理化和系统化。结果表明,对医药业物流指数具有直接影响的是库存成本、产品特性与价值、人员素质以及物流信息化程度。     

江苏省医药产业竞争力比较分析与策略探讨

江苏省是中国医药经济比较发达的省份之一,在全国医药经济中占有重要地位。近年来,江苏医药产业保持快速发展势头,但同时也暴露出创新能力、人力资源和产业集中度等方面的问题。对江苏省医药产业的发展状况分析的基础上。选取主要竞争力评价指标对江苏省和中国一些重点省市医药产业的竞争力进行比较分析,针对性地提出提升江苏医药产业竞争力的对策建议。     

中国医药制造业产业集聚实证研究

产业集聚程度是衡量一个产业竞争优势的重要指标,通过计算基尼系数、集中率及赫希曼·哈菲德尔指数等指标,对中国医药制造业产业集聚水平进行了实证分析,并通过对排名在前八位的省市做进一步的研究,得出结论:中国医药制造业的产业集聚水平很低,主要分布在东部地区几个省份.作为规模经济性较强的高技术产业,中国医药制造业只有提高产业集聚水平才能获得并保持持久的竞争优势.     

基于知识链的制药产业协同创新研究——以我国医药制造业为例

基于知识链角度,分析我国制药产业协同创新系统结构模型及各子系统间的相互关系;结合复合系统协同度模型,以我国医药制造业为例,从知识创新投入、知识转化、知识价值实现以及创新环境对知识创新的支撑能力4个方面,确定反映其各子系统协同创新的序参量,并对医药制造业协同创新系统的协同性进行测度。结果表明,我国医药制造业创新系统有序度仍存在较大的提升空间。因此,建议加强政府引导和监管职能,完善产学研协同创新体系,提升知识产权服务能力,拓宽医药制造业融资渠道。     

Mind the Gap: Information and Communication Technologies, Knowledge Activities and Innovation in the Pharmaceutical Industry

The paper explores the specific challenges facing the pharmaceutical industry regarding the exploitation of information and communication technologies (ICTs) in the context of developing new frameworks supporting knowledge activity and the wider innovation process. The paper seeks to provide a framework to view these changes but also highlights gaps in our current conceptualization of the role of ICTs in facilitating and effecting change within the pharmaceutical industry.     

Mind the Gap: Information and Communication Technologies,Knowledge Activities and Innovation in the Pharmaceutical Industry

The paper explores the specific challenges facing the pharmaceutical industry regarding the exploitation of information and communication technologies (ICTs) in the context of developing new frameworks supporting knowledge activity and the wider innovation process. The paper seeks to provide a framework to view these changes but also highlights gaps in our current conceptualization of the role of ICTs in facilitating and effecting change within the pharmaceutical industry.     

基于SCP框架的中国医药制造业产业组织研究

改革开放以来,中国医药制造业快速发展,在保障人民健康方面做出了重要贡献。但与世界医药制造业大国相比。中国还有明显差距。为此,推进中国医药制造业的并购和重组、加大医药制造业的R＆D投入和加强医药制造业的政府管制是提升市场竞争力的必然选择。     

The Strategic Management of Mergers and Acquisitions in the Pharmaceutical Industry: Developing a Resource-based Perspective

There is a growing recognition within resource-based theory that mergers and acquisitions (M&A) can play an important role as a means of transferring otherwise non-marketable resources and capabilities. However, this resource-based view has yet to consider in detail the management process issues involved. This paper looks at three cases from the pharmaceutical industry and seeks to begin the development of a resource-based perspective on the management of M&A.     

The Strategic Management of Mergers and Acquisitions in the Pharmaceutical Industry: Developing a Resource-based Perspective

There is a growing recognition within resource-based theory that mergers and acquisitions (M&A) can play an important role as a means of transferring otherwise non-marketable resources and capabilities. However, this resource-based view has yet to consider in detail the management process issues involved. This paper looks at three cases from the pharmaceutical industry and seeks to begin the development of a resource-based perspective on the management of M&A.     

Using Bibliometrics to Measure Firm Knowledge: An Analysis of the US Pharmaceutical Industry

A recent literature review highlighted the knowledge-based view as an important current theory in the strategic management area. The current paper utilizes that theory as the context for employing bibliometrics to uncover the publishing and patenting citation patterns in a group of twelve US pharmaceutical companies over a 13-year period. Our initial findings suggest that firms self-cite a great deal, and that they rely heavily on public science. In addition, we found that Merck and Co. is the most frequently cited company in both the science and technology areas, though somewhat less so in technology. The managerial implications, particularly from a knowledge perspective, are discussed as well as some suggestions for future research.     

Using Bibliometrics to Measure Firm Knowledge: An Analysis of the US Pharmaceutical Industry

A recent literature review highlighted the knowledge-based view as an important current theory in the strategic management area. The current paper utilizes that theory as the context for employing bibliometrics to uncover the publishing and patenting citation patterns in a group of twelve US pharmaceutical companies over a 13-year period. Our initial findings suggest that firms self-cite a great deal, and that they rely heavily on public science. In addition, we found that Merck and Co. is the most frequently cited company in both the science and technology areas, though somewhat less so in technology. The managerial implications, particularly from a knowledge perspective, are discussed as well as some suggestions for future research.     

药品专利保护对医药产业发展贡献度的实证分析

在医药技术、医药经济和医药产业倍受关注的今天,药品专利保护所具有的激励研发创新、提升科技竞争力、促进信息技术公开的基本功能,已经成为医药产业实现跨越式发展的有力保障。实证分析药品专利保护对医药产业发展的贡献度可知,按照1995-2007年我国医药行业工业增加值的平均增长率计算,药品专利制度的贡献率为29.2%,资本的贡献率为13.0%,科技活动人员的贡献率为57.8%。     

国际医药企业购并动因分析及对中国的启示

本文分析了国际医药企业购并的动因，借鉴其经验，提出了对我国医药企业购并的启示。